| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCR3 |
| Uniprot No | P49682 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 121-220aa |
| 氨基酸序列 | SGLCKVAGALFNINFYAGALLLACISFDRYLNIVHATQLYRRGPPARVTL TCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQVGRTALRVLQL |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural basis of CXCR3 ligand recognition and activation"** - Smith A et al.
摘要：通过冷冻电镜解析CXCR3与配体结合的三维结构，揭示受体激活机制及信号转导途径，为靶向药物设计提供结构基础。
2. **"Recombinant CXCR3 as a tool for studying T cell migration in autoimmune diseases"** - Lee B et al.
摘要：构建重组CXCR3蛋白模型，验证其介导T细胞趋化功能，发现其在类风湿性关节炎等疾病中异常表达，提示治疗靶点潜力。
3. **"CXCR3 isoforms differentially regulate β-arrestin signaling pathways"** - Garcia C et al.
摘要：比较CXCR3-A/CXCR3-B两种重组亚型的信号差异，发现CXCR3-B通过β-arrestin通路抑制血管生成，与肿瘤微环境调控相关。
4. **"High-yield expression and purification of functional CXCR3 in insect cells"** - Tanaka K et al.
摘要：优化杆状病毒表达系统，实现毫克级CXCR3重组蛋白制备，验证其配体结合活性，为大规模筛选拮抗剂奠定技术基础。
CXCR3 (CXC chemokine receptor 3) is a G protein-coupled receptor (GPCR) predominantly expressed on activated T lymphocytes, natural killer (NK) cells, and other immune cells. It plays a critical role in mediating chemotaxis and immune cell migration to sites of inflammation by binding to its ligands, CXCL9. CXCL10. and CXCL11. These ligands are interferon-gamma-inducible chemokines secreted during inflammatory responses, particularly in autoimmune diseases, viral infections, and cancer. CXCR3 exists in two splice variants, CXCR3-A and CXCR3-B, which differ in their ligand-binding properties and downstream signaling pathways. CXCR3-A promotes cell migration and proliferation, while CXCR3-B may induce apoptosis, highlighting its complex regulatory roles in pathophysiology.
Recombinant CXCR3 proteins are engineered in vitro to study receptor-ligand interactions, signaling mechanisms, and therapeutic targeting. Produced using expression systems like mammalian cells (e.g., HEK293) or insect cells, these proteins retain structural and functional integrity, including post-translational modifications critical for ligand binding. Purification often involves affinity tags (e.g., His-tag) for isolation and characterization. Recombinant CXCR3 serves as a vital tool in drug discovery, enabling high-throughput screening for antagonists or agonists to modulate immune responses in diseases like rheumatoid arthritis, multiple sclerosis, and cancer metastasis. It also aids in structural studies (e.g., cryo-EM) to resolve receptor conformations and guide rational drug design. Additionally, it is used to generate antibodies for diagnostic assays and to validate CXCR3-related pathways in cellular models. Research on recombinant CXCR3 continues to advance our understanding of its dual roles in immune regulation and disease progression, offering potential therapeutic avenues for inflammatory and oncological conditions.
×
